



## INDEX

- A4M, 192, 195, 199
- AA. *See* Alzheimer's Association
- active aging, 103, 185
- ACTIVE trial, 116–17
- activities of daily living (ADLs), 43, 48, 116–17
- AD. *See* Alzheimer's disease
- AD dementia, 85n1
- ADLs. *See* activities of daily living
- ADRDA. *See* Alzheimer's Disease and Related Disorders Association
- aducanumab, 48–49, 246
- affective economies, 200
- ageism, 79–80, 200, 206
- aging. *See also* anti-aging; successful aging
- active, 103, 185
  - brain, 33–34
  - cancer associated with, 181–82, 185, 188n9
  - dementia association with, 2, 51, 181–82, 185
  - fear of, 200–201
  - functional decline with, 110–16
  - healthy, 121–22
  - medicalization of dementia and, 102–4
  - normal trajectories of, 112–16
  - normative standards of, 200, 206–7
  - preparation for, 12
  - public health measures for, 33–34
  - responsibilization of, 193–94, 197–201, 203–8
  - as threat to autonomy, 142–43
- alcohol use, 175, 215, 229
- Alzheimer, Alois, 2, 6, 21–25, 27, 36n4, 47, 133
- Alzheimer's Association (AA), 26, 29
- biological definition of Alzheimer's disease, 20–21, 30, 36n3
  - brain health education program, 42
  - cure goal of, 242–43
- Alzheimer's disease (AD)
- amyloid plaques and neurofibrillary tangles in, 44–45
  - biological definition of, 20–21, 30–34, 36n3, 43
  - biomarkers of, 6, 30–32, 43–44, 66–67, 69–71, 76, 86n2, 113, 132–33, 136–37, 153–55
  - biomedical models of, 19, 35n1
  - BPSD symptoms and, 42–50, 58nn3–4
  - classification of, 21–35
  - clinical symptoms of, 23–25, 29–32, 34
  - conceptual foundations of, 19–35
  - continuum, 30, 66–67, 85n1, 102, 110–11, 131–37, 151–56, 166n3
  - cure versus prevention of, 242–49
  - definitions of, 85n1
  - as democratic versus undemocratic disease, 55–57, 58nn8–9
  - as disease of second stage of life, 74, 79–80
  - early detection of, 29, 32, 43–44, 113, 131–33, 153–56
  - ethics of prediction of, 67–71, 78–84, 86n3
  - etymology of, 245–46
  - first case of, 22, 36n5
  - German debate over, 65–84, 98–99
  - historical perspective of, 19–32, 133–35
  - medical shift from cure to prevention of, 66–67
  - mysteriousness of, 47–50, 53, 56, 58n7

- neoliberalism shaping of, 246–47
- as organic brain disease, 22–23
- pathological process of, 23–28, 30–31, 34, 183
- politicization of, 26–27
- public health measures for, 33–34
- research paradigm for, 132–37
- social representation of, 33
- stages of, 66–67, 85n1, 131–33, 166n3
- subgroups of, 56–57
- subjective experience of, 158–64
- success in prevention of, 248–49
- as syndrome, 6, 14n4, 30, 43, 46, 245–46
- trajectory of, 19, 36n2
- vascularization of, 42–57, 112–13
- window to act in, 19–21, 30–32, 43
- as working title, 19, 32–35
- Alzheimer's Disease and Related Disorders Association (ADDA), 26–27
- amyloid hypothesis, 47–50, 132, 135–36
- amyloid plaques
  - as AD biomarker, 30–31, 154–55
  - in senile dementia, 44–45
  - uncertainty about, 47–50
- anti-aging
  - dementia as worst-case scenario in, 207
  - goals of, 195
  - individual responsibility in, 192–94, 197–201, 203–8
  - origin of, 194–95, 209n1
  - paradigm of prevention and, 194–97
- anti-amyloid therapies, 136, 155, 214, 246
- APOE gene, 46, 68
- apolipoprotein E, 46
- Archives of Neurology*, Katzman editorial in, 26–28, 36n8
- asymptomatic at-risk state for AD, 85n1
- atherosclerosis, 44–45, 56
- autonomy, 81, 142–43, 146
- behavioral and psychological symptoms of dementia. *See* BPSD
- behavior modification, government influence on, 230–31
- beta-amyloid. *See* amyloid plaques
- bioethics
  - of dementia prediction, 67–71, 78–84, 86n3
  - discourse analysis in, 69–70
  - of MCI diagnostic, 147–48
- biographical disruption, 161–63
- biomarkers
  - AD, 6, 30–32, 43–44, 66–67, 69–71, 76, 86n2, 113, 132–33, 136–37, 153–55
  - ethics of AD prediction by, 69–71
- biomedicine
  - AD models of, 19, 35n1
  - chronic disease prevention approaches of, 180
  - cures sought by, 244
  - models beyond models of, 243–44
- biopolitics
  - responsibility for lifestyle, 218–19
  - responsibilization of aging, 198
- biopsychosocial models, 243–44
- body-brain connection, 3–5
- BPSD (behavioral and psychological symptoms of dementia), 42–50, 58nn 3–4
- brain aging, AD as, 33–34
- brain-as-body, 4–5
- brain-centeredness, 3–4
- brain disease. *See* organic brain disease
- brain health
  - AA education program on, 42
  - market serving, 156–58, 166n4
  - as moral imperative of dementia prevention, 78–79
  - through public health, 249
- brain training. *See* cognitive training
- Brazil
  - dementia epidemiology in, 51, 58n5
  - ethnography data on moral citizenship in, 50–55
  - modifiable risk factors in, 51–55
  - pharmaceuticals sales representatives in, 48
- calorie restriction, 118
- campaigns of dementia prevention
  - collective dimension of, 97–101, 105–6
  - critical assessment of, 102–6
  - Eisai, 20
  - improbability of, 93–98, 107n6

- in Switzerland, 92, 96, 100, 106n1
- Canada. *See* Health Field Concept
- cancer, 175, 178
  - lifestyle frame and, 181–85, 187–88nn6–9
  - Nixon’s war on, 26
- capitalism, 244–48
- capitalization, of MCI, 155
- cardiovascular disease, 46, 175, 178, 180
- cardiovascular logic, 46, 56, 112–13, 183–84. *See also* vascularization of Alzheimer’s disease
- cardiovascular risk factors, 40–41, 57n1, 58n2
  - in discourse on dementia prevention, 72–75, 77–78
  - in vascularization of AD, 45–47, 50–56, 112–13
- care
  - cure separation from, 243
  - shift to prevention from, 66–67
- cerebral atherosclerosis, 44–45, 56
- chain of translations, 101, 106
- cholinesterase inhibitors, 46, 155
- chronic illness
  - concept of prevention and, 176–78
  - lifestyle frame for prevention of, 175–86
  - modifiable risk factors in, 175–76, 182, 187n6
  - prevention at different points of, 179–81
  - self-management programs, 180, 187n5
- classification
  - of AD, 21–35
  - of prevention, 81–82, 179–81, 183
- classificatory drift, of MCI, 131–48
- clinical symptoms, of AD, 23–25, 29–32, 34
- cognitive function. *See also* functional decline
  - dementia as disruption of, 110–12
- cognitive health. *See* brain health
- cognitive impairment. *See also* mild cognitive impairment
  - subjective experience of, 158–64
- cognitive inactivity, 215
- cognitive paradigm, BPSD challenge of, 42–43
- cognitive reserve, 51–53, 58n6, 116–17
- cognitive training, 1, 78–79, 116–17, 156–58, 166n4
- cognito-politics, 156–57
- collective responsibility
  - environmental issues as, 107n4
  - in healthy lifestyle promotion, 97–101, 105–6
- commercialization, of cure, 245–46
- Commission on Chronic Illness, 176–86
- communication theory, 93, 96–97, 107n6
- community participation, 93
- consumerism, MCI category as function of, 138–46
- continuum, of AD, 30, 66–67, 85n1, 102, 110–11, 131–37, 151–56, 166n3
- Covid-19 pandemic, 243
- critical gerontology
  - responsibilization of aging discussion in, 193, 197–201, 203–8
  - successful aging and anti-aging in, 194–96
- cultures of action, 188n8
- cure
  - care separation from, 243
  - challenges to, 244–45
  - language of, 245–46
  - politics of, 246–48
  - prevention versus, 242–49
  - shift to prevention from, 66–67
- DAlzG. *See* Deutsche Alzheimer Gesellschaft
- danger, risk versus, 94–95
- deafness. *See* hearing loss
- dementia. *See also specific topics*
  - aging association with, 2, 51, 181–82, 185
  - as disruption of cognitive functions, 110–12
  - etymology of, 245–46
  - fear of, 157–58
  - lifestyle frame and, 181–86
  - medicalization of, 102–4
  - normalization of, 115–16, 119–22
  - normal states versus, 102–4, 110–15
  - prevalence of, 214, 216
  - WHO action plan for, 214–17
  - as worst-case scenario of anti-aging movement, 207
- “Dementia Can Affect Everyone” campaign, 92–93

- dementia puzzle, 6
- democratic disease, AD as, 55–57, 58n8–9
- depression, 1, 47, 51, 57n1, 215
- determinants of health, 180, 216
- Deters, Auguste, 22, 47
- Deutsche Alzheimer Gesellschaft (DAzG), 77–78
- diabetes, 1, 6, 41, 51–56, 57n1, 175, 215
- Diagnostic and Statistical Manual of Mental Disorders (DSM-5)*, 29–30, 153
- diagnostic “it,” 160–61
- diet, 1, 57n1, 117–18, 175, 180, 215
- disclosure, of predictive information, 67
- discourse of dementia prevention, 65–66
  - media, 70–73, 75–77, 79, 82–84
  - patient advocacy groups, 77–79, 84
  - popular scientific, 70–73, 75–77, 79, 82–84
  - professional, 69–74, 76–77, 79, 82–84
- discrimination, in ethics of dementia
  - prediction, 71, 79–80
- DSM-5*. *See Diagnostic and Statistical Manual of Mental Disorders*
- early-onset dementia, late-onset dementia versus, 5
- ecology, in prevention, 243–44
- ecopsychosocial models, 244
- education
  - as dementia risk factor, 1, 8, 47, 51–56, 57n1, 58n2, 58n6, 215
  - in German AD debate, 76–77
- EMERGE and ENGAGE studies, 48–50
- environmental factors, 4–5
  - in chronic disease prevention, 187n6
  - as collective responsibility, 107n4
  - in Health Field Concept, 232–33
  - in healthy aging model, 121–22
- epidemiological studies, in Brazil, 51, 58n5
- epistemic changes in dementia prevention, 40–41
  - frailty considerations, 111–15
  - normalization of dementia, 115–16, 119–22
  - vascularization of AD, 42–57, 112–13
- ethics
  - of dementia prediction, 67–71, 78–84, 86n3
  - of governmentality, 225
  - of MCI diagnostic, 147–48
  - of moral economy of prevention, 197–201, 207–8
  - prevention, 8–9
  - public health, 8–9, 68, 80–84
  - of responsibility claims, 193–94, 201–8
- etymology, of prevention versus cure, 242–49
- exercise. *See physical activity*
- fasting, 118
- First Nations populations, dementia among, 216
- frailty, mind, 110–11
  - healthy aging model and, 121–22
  - as modifiable risk factor, 113–16
  - normal trajectories of, 112–16
  - prevention of, 116–21
- France, hygiene movement in, 98
- functional decline
  - age-related, 110–16
  - lifestyle-based preventive measures for, 116–21
  - normal trajectories of, 112–16
  - subjective experience of, 158–64
- futurity, 156–57
- genetics, 5, 180
- genetic testing, ethics of, 67–71, 86n3
- geriatrics, 110
  - healthy aging model in, 121–22
  - normal trajectories of functional decline, 112–16
  - prevention of functional decline, 116–21
- Germany
  - AD debate in, 65–84, 98–99
  - genetic testing law in, 69
  - prescription cost responsibility in, 100
- geroprotectors, 111, 118–20
- governmentality, 93
  - Health Field Concept, 220, 224–26, 234–36
  - prevention, 217–20, 224–26, 230, 236
- ground-state prevention, 112, 120–21
- HD. *See Huntington’s disease*

- health
- definition of normal in, 102–4, 110–12
  - determinants of, 180, 216
  - individual responsibility for, 192–94, 197–201, 203–8
  - value of, 97–98
- health care access, 51–55
- health-care organization, in Health Field Concept, 232–33
- Health Field Concept
- elements of, 217, 219, 228–34
  - environmental factors in, 232–33
  - genealogical analysis of, 236
  - in global public health policies, 219, 222–24, 236
  - governmentality and, 220, 224–26, 234–36
  - health-care organization in, 232–33
  - historical narrative on prevention and, 226–28
  - human biology in, 234
  - introduction of, 221–24
  - lifestyle in, 217, 219, 228–31, 234–36
  - as mode of governing, 234–35
- health insurance, healthy lifestyle promotion by, 216
- healthism, 206
- health market
- for cognitive fitness, 156–58, 166n4
  - cure commercialization in, 245–46
  - MCI as diagnostic category serving, 138–46
- health promotion. *See also* campaigns of dementia prevention
- health marketing for, 230–31
  - Lalonde report role in, 217, 220
  - lifestyle focus in, 175, 180
- Health Promotion Directorate (HPD), Canada, 231
- healthy aging, 121–22
- Healthy Habits for a Healthier You* (AA), 42
- healthy lifestyle. *See* lifestyle
- hearing loss, 1, 57n1, 78
- heart disease. *See* cardiovascular disease
- holistic approach, in German debate on dementia prevention, 72–74, 83
- hope, lifestyle as source of, 184–85, 188n8
- HPD. *See* Health Promotion Directorate
- human biology, in Health Field Concept, 234
- Huntington's disease (HD), 86n3, 160
- hypertension, 1, 6, 51–56, 57n1, 74, 77, 215
- hypochondria, 105
- ideologization, in responsabilization of aging, 199–200, 205–7
- ilSIRENTE trial, 117
- incentive programs, 83, 86n10
- indicated recommendations, 82
- Indigenous peoples, dementia among, 216
- individualization, in responsabilization of aging, 198, 203–4, 207
- individual responsibility
- expansion of, 93–106
  - in German debate on dementia prevention, 75–78, 80, 82–84
  - for lifestyle, 215–19, 225, 228–29, 234–36
  - in neoliberalism, 93–94, 98–106, 224–26, 228–29, 246–48
  - for successful aging, 192–94, 197–201, 203–8
- inequality, 104
- instrumentalization, in responsabilization of aging, 199, 205–7
- International Psychogeriatric Association (IPA), 43, 58n4
- intrinsic capacity, 120–22
- IPA. *See* International Psychogeriatric Association
- Katzman, Robert, 26–28, 36n8
- Kraepelin, Emil, 21–25, 36n4, 36n7
- Lalonde report, 236. *See also* Health Field Concept
- creation and international significance of, 221–24
  - lifestyle change rationale in, 228–31
  - paradigm shift of, 217–21, 225–28
- Lancet* report
- new dementia in, 1–9, 175
  - risk factors named in, 1–7, 40–41, 57n1
- late-onset degenerative disease, ethics of genetic testing for, 68–71
- late-onset dementia, early-onset dementia versus, 5

- life experience, 115–16, 122n1
- lifestyle
- cancer and, 181–85, 187–88nn6–9
  - collective dimension of, 97–101, 105–6
  - critical assessment of promotion of, 102–6
  - dementia and, 181–86
  - as frame for chronic disease prevention, 175–86
  - genealogical analysis of role of, 216–17, 226–28
  - in Health Field Concept, 217, 219, 228–31, 234–36
  - health insurance promotion of, 216
  - improbability of, 93–98, 107n6
  - individual responsibility for, 215–19, 225, 228–29, 234–36
  - as major determinant of health, 180
  - market targeting, 156–58, 166n4
  - moderation of, 104–5
  - as public health central focus, 175–76, 180, 184–86, 187n1, 187n4
  - as source of hope, 184–85, 188n8
- lifestyle recommendations. *See also* risk factors
- for functional decline prevention, 116–21
  - in German AD debate, 65–66, 73–80, 82–83
  - public health measures versus, 98–101, 105–6
  - researcher resistance to, 45
  - situatedness of, 41–42
  - as source of hope, 184–85, 188n8
  - in WHO action plan for dementia prevention, 214–17, 219, 236
- MacArthur Foundation, 199
- market. *See* health market
- marketization
- MCI category as function of, 138–46
  - of social responsibilities, 102–4
- MCI. *See* mild cognitive impairment
- McKhann criteria, 134
- media discourse, on dementia prevention, 70–73, 75–77, 79, 82–84
- medicalization, 102–4
- memantine (Namenda), 47, 155
- memory complaints, MCI diagnosis, 131–46
- metaphor, 158–64
- metformin, 119–20
- mild cognitive impairment (MCI)
- in AD continuum, 66–67, 131–37, 151–56
  - capitalization of, 155
  - classificatory drift of, 131–48
  - clinical criteria for, 152–53
  - clinical relevance of, 29
  - definition of, 152, 166n3
  - diagnostic category of, 131–46
  - diagnostic uncertainty of, 147–48
  - epistemic changes linked to dementia prevention and, 42–50, 113
  - ethics of AD prediction by, 70–71
  - expert reflections on, 152–56
  - frailty effects in, 114
  - individualization in diagnosis of, 143–46
  - market role in diagnostic category of, 138–46
  - market serving, 156–58, 166n4
  - postdiagnosis support for, 156, 159–60, 165
  - preventive uncertainty of, 151–65
  - psychosocial consequences of, 137
  - subjective experience of, 158–64
  - subjective memory complaints necessitating category of, 132–33, 137–46
  - 2001 versus 2018 guidelines on category of, 131–33
- mixed dementia, 45–47
- modifiable risk factors. *See* risk factors
- monofactorial strategies in dementia prevention, 75–77, 82
- moral citizenship, vascularization of AD and, 50–55
- moral economy, of prevention, 197–201, 207–8
- moral imperatives, of dementia prevention, 78–80
- multimodal strategies in dementia prevention, 72–74, 79, 83
- NA. *See* National Institute of Aging
- Namenda. *See* memantine

- NAPA. *See* National Alzheimer's Project Act
- narrative  
 Health Field Concept changes to, 226–28  
 in subjective experience of cognitive impairment, 158–64
- narrative collision, 163–65
- National Alzheimer's Project Act (NAPA), 42
- National Cancer Act, 26
- National Dementia Strategy, Switzerland, 92, 96, 100, 106n1
- National Institute of Aging (NIA), 29, 30, 44, 133–34
- National Institutes of Aging and Alzheimer's Association (NIA-AA), 20–21, 30, 36n3, 153
- Nehls, Michael, 65–66
- neoliberalism, 246–49  
 health-care organization in, 232–33  
 individual responsibility in, 93–94, 98–106, 224–26, 228–29, 246–48  
 lifestyle frame as product of, 181  
 public health management approaches of, 217–21, 224–26, 236  
 social democracy versus, 248  
 socioeconomic factors neglected in, 216  
 successful aging as paradigm of, 103
- neurodegeneration, 30–31
- neurofibrillary tangles, 44–45
- neuroplasticity, 5  
 brain health market and, 157  
 new dementia similarities to, 56
- Newcastle study, 44
- new dementia  
 as disease of second stage of life, 74, 79–80  
 ethics of, 67–68, 79–80, 84  
*Lancet* report framing of, 1–9, 175  
 patienthood status related to, 67  
 reflections on, 1–12, 14nn2–3  
 situatedness of, 8–9, 40–41  
 subgroups of, 56–57  
 terminology of, 85n1  
 vascularization of AD aspect of, 42–57, 112–13
- NIA. *See* National Institute of Aging
- NIA-AA. *See* National Institutes of Aging and Alzheimer's Association
- Nixon, Richard, 26
- normal  
 aging trajectories, 112–16  
 pathological versus, 102–4, 110–12, 178
- normalization, of dementia, 115–16, 119–22
- nutrition, 47, 117–18
- obesity, 1, 41, 73, 215
- organic brain disease, 22–23
- Ottawa Charter on Health Promotion*, 223
- overexpansion, in resensibilization of aging, 198–99, 204, 207
- Pasteur, Louis, 98
- pathological process  
 of AD, 23–28, 30–31, 34, 183  
 normal versus, 102–4, 110–12, 178
- patient advocacy, 67, 77–79, 84, 188n8
- patient autonomy, 81, 142–43, 146
- patienthood, in new dementia, 67
- personal identity, disruption of, 110, 161–63
- personalization, of MCI diagnosis, 143–46
- personal responsibility. *See* individual responsibility
- pharmacological interventions  
 AD research paradigm and, 134–36  
 failure of, 48–50, 136, 214, 246  
 in German AD debate, 74–75  
 for MCI, 155  
 new targets of, 43, 48  
 situatedness of, 41–42
- physical activity  
 for functional decline prevention, 117  
 in German AD debate, 73–78, 82–83  
 as modifiable risk factor, 1, 57n1, 73, 175, 215
- plasticity. *See* neuroplasticity
- politicization, of AD, 26–27
- politico-epistemic scaffold, MCI category as, 132–33
- politics. *See also* neoliberalism  
 of anti-aging medicine, 199–200  
 of cure, 246–48  
 of dementia prevention, 156–57, 184–85, 188n8, 244–49

- as preventative measure for dementia, 248
  - of responsibility for lifestyle, 218–19
- pollution, 1, 7, 57n1
- popular scientific discourse, on dementia prevention, 70–73, 75–77, 79, 82–84
- poverty, 47, 53–55, 104
- power, in Health Field Concept, 228–31
- preclinical AD, 85n1, 153–56
- predementia, 85n1, 166n3. *See also* mild cognitive impairment
- prediction
  - ethics of, 67–71, 78–84, 86n3
  - medical shifts to prevention from, 66–67
- PreDiva study, 40–41
- presymptomatic AD, 85n1
- prevention. *See also* epistemic changes in dementia prevention; risk factors
  - AD research paradigm and, 132–37
  - classification of, 81–82, 179–81, 183
  - collective dimension of, 97–101, 105–6
  - concept of, 176–78
  - critical assessment of, 102–6
  - cure versus, 242–49
  - cybernetic and systematic approach to, 66
  - discourse analysis of, 65–66, 69–79, 82–84
  - ecology in, 243–44
  - economic benefits of, 196–97, 199–200
  - ethical issues in, 67–71, 78–84, 86n3
  - ethics frameworks for, 8–9
  - of functional decline, 116–21
  - geriatric logic in clinical discourse about, 110–22
  - governmentality of, 217–20, 224–26, 230, 236
  - ground-state, 112, 120–21
  - Health Field Concept changes to
    - narrative of, 226–28
  - as heart-brain prevention, 72–74
  - history of, 42
  - improbability of, 93–98, 107n6
  - individual responsibility for, 192–94, 197–201, 203–8
  - Lancet* report on modifiable risk factors for, 1–7, 40–41, 57n1
  - language of, 242–49
  - lifestyle as frame for, 175–86
  - medicalization of dementia and, 102–4
  - medical shifts from prediction to, 66–67
  - moral economy of, 197–201, 207–8
  - moral imperatives of, 78–80
  - new pathways for, 47–50
  - obsession with, 104–5
  - politics of, 156–57, 184–85, 188n8, 244–49
  - primary, 6, 32, 68, 81–82, 179–80, 183
  - secondary, 6, 68, 81–82, 179, 183
  - situatedness of, 8–9, 40–42
  - successful aging and anti-aging as
    - symptoms of paradigm of, 194–97
  - success of, 248–49
  - tertiary, 7, 81–82, 179–80, 183, 187n5
  - unknowns in, 95–97
  - WHO action plan for, 214–17, 219–20, 226, 235–36
  - window to act in, 19–21, 30–32, 43
- preventive horizon, 104
- preventive self, 98–101, 104, 106
- primary prevention, 6, 32, 68, 81–82, 179–80
- privatization
  - of health-related responsibility, 92–101, 105–6
  - of risk management, 218–19
- privatized health-care systems, moral economy of prevention in, 208
- prodromal AD, 85n1
- professional discourse, on dementia prevention, 69–74, 76–77, 79, 82–84
- prospective responsibility, 192–93, 201–2, 205
- psychological symptoms of dementia. *See* BPSD
- public health
  - brain health through, 249
  - chronic illness prevention, 176–86
  - Covid-19 pandemic and, 243
  - environment enhancement measures for old people, 33–34
  - in German debate on dementia prevention, 80–84, 98–99



- Health Field Concept in, 217–36
- individual responsibility versus  
responsibility of, 93–94, 98–106
- Lalonde report influence on global,  
217
- lifestyle as core focus of, 175–76, 180,  
184–86, 187n1, 187n4
- lifestyle responsibility in, 215–19,  
225, 228–29, 234–36
- neoliberalism in, 217–21, 224–26,  
236
- prevention as governmentality in, 236
- vascular dementia prevention  
recommendations, 45
- WHO action plan for dementia  
prevention, 214–17
- public health-care systems, moral economy  
of prevention in, 208
- public health ethics, 8–9, 68, 80–84
- quality of life, 48
- rapamycin, 119
- resilience, 121–22  
diet, 117–18  
geroprotectors boosting, 119
- responsibility. *See also* social responsibilities;  
individual responsibility  
collective, 97–101, 105–6, 107n4  
concept of, 201–2  
ethics of claims of, 193–94, 201–8  
for lifestyle, 215–19, 225, 228–29,  
234–36  
privatization of health-related, 92–  
101, 105–6  
prospective and retrospective, 192–93,  
201–2, 205  
for self-care, 51–55
- responsibilization of aging, 193–94, 197–  
201, 203–8
- retrospective responsibility, 192–93,  
201–2, 205
- risk  
danger versus, 94–95  
patients living with uncertainty of,  
158–65
- risk factors, 92–93, 107n2, 178. *See also*  
*specific risk factors*  
amyloid hypothesis uncertainty and,  
49–50  
in Brazil, 51–55  
in chronic illness, 175–76, 182,  
187n6  
common dementia, 51  
frailty as, 113–16  
in German AD debate, 65–66, 72–78  
history of, 42  
individual responsibility for, 215–19,  
225, 228–29, 234–36  
intrinsic capacity as, 121–22  
*Lancet* report on, 1–7, 40–41, 57n1  
“new,” 3, 8, 47, 51–55  
overextension of responsibility for, 204  
in WHO action plan for dementia  
prevention, 214–17, 219, 236
- risk management, privatization of, 218–19
- risk reduction, 6–7
- Roses, Allen, 46
- SCD. *See* subjective cognitive decline
- screening programs, 179–80
- secondary prevention, 6, 68, 81–82, 179,  
183
- second stage of life, AD as disease of, 74,  
79–80
- selective optimization with compensation  
(SOC), 195
- selective recommendations, 82
- self-care, in Brazil, 51–55
- self-efficacy, 84
- self-management programs, chronic illness,  
180, 187n5
- self-stigmatization, 71
- senile dementia, 44–45  
as chronic illness, 181–83  
Katzman conceptualization of, 26–27  
Kraepelin and Alzheimer research on  
AD compared with, 21–24, 36n4
- senility, 178
- senolytics, 119
- situatedness  
of dementia prevention, 8–9, 40–42  
of discourse, 70
- sleep, 1, 57n1
- smoking, 1, 57n1, 73, 95, 175, 178, 182,  
215, 229
- SOC. *See* selective optimization with  
compensation
- social democracy, as preventative measure  
for dementia, 248

- social determinants of health, 216
- social isolation, 1, 57n1, 215
- social phenomena, emergence of, 98
- social responsibilities  
 expansion of, 100–101, 105–6  
 in German debate on dementia prevention, 80–84, 98–99  
 marketization of, 102–4
- society  
 active, 103  
 dementia prevention establishment in, 97–101, 105–6
- socioeconomic factors, 216
- sociology of aging  
 responsabilization of aging discussion in, 193, 197–201, 203–8  
 successful aging and anti-aging in, 194–96
- statins, 75
- stigmatization  
 in ethics of dementia prediction, 71, 79–80, 82, 84  
 of MCI diagnosis, 137  
 in responsabilization of aging, 200–201, 205, 207
- stroke, 45–46, 53, 161
- Study on Successful Aging* (MacArthur Foundation), 199
- subjectivation, in Health Field Concept, 228–31
- subjective cognitive decline (SCD), 67, 166n3
- subjective memory complaints, 132–33, 137–46
- successful aging, 185  
 definition of, 103–4  
 dementia as worst-case scenario in, 207  
 individual responsibility for, 192–94, 197–201, 203–8  
 models of, 195  
 as neoliberalism paradigm, 103  
 paradigm of prevention and, 194–97  
 resilience and, 122
- susceptibility genetic testing, 68–69
- Switzerland, dementia campaigns and strategies in, 92, 96, 100, 106n1
- Tacrine, 46–47
- tau protein, 30–31, 48–49, 154–55
- techno-economic promise, of AD research, 134–36
- technologies of self, 225, 228–31
- tertiary prevention, 7, 81–82, 179–80, 183, 187n5
- tobacco use. *See* smoking
- translation, of health education information, 101, 106
- undemocratic disease, AD as, 55–57, 58nn8–9
- Unified Theory of Alzheimer's disease (UTAD), 65–66
- United States  
 chronic illness prevention in, 176–86  
 dementia rate decline in, 41  
 Lalonde report influence in, 223
- universal recommendations, 81–82
- UTAD. *See* Unified Theory of Alzheimer's disease
- vascular dementia (VaD), 44–47, 53–57
- vascularization of Alzheimer's disease, 42–57, 112–13
- WHO. *See* World Health Organization
- window to act, 19–21, 30–32, 43
- World Health Organization (WHO)  
 chronic illness references of, 185–86  
 dementia prevention action plan of, 214–17, 219–20, 226, 235–36  
 dementia risk reduction recommendations of, 68  
 Health Field Concept dissemination by, 222–23  
 healthy aging model of, 121–22